Picture of Hyperfine logo

HYPR — Hyperfine News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Portable MRI maker Hyperfine's Q3 prelim revenue beats estimates; FY outlook reaffirmed

Portable MRI maker Hyperfine's Q3 prelim revenue beats estimates; FY outlook reaffirmed


Overview

  • US portable MRI maker's preliminary Q3 revenue grew 53% sequentially, beating analyst expectations

  • Company reaffirmed full-year 2026 revenue outlook of $20-22 mln

  • Q3 revenue exceeded net cash burn for first time, showing improved operating leverage


Outlook

  • Hyperfine reaffirms 2026 revenue outlook of $20 mln to $22 mln

  • Company maintains 2026 net cash burn guidance at $26 mln to $28 mln

  • Company sees continued adoption across hospital, office-based, wellness, and international markets


Result Drivers

  • COMMERCIAL EXPANSION - Co cited strong momentum across health systems, new care sites, and international rollout of Model 2 Swoop system

  • OPERATING DISCIPLINE - Co said lower cash burn reflected improved operating discipline in Q3

  • NEW CARE SETTINGS - Co highlighted adoption of its portable MRI in office-based, wellness, and mobile settings


Company press release: ID:nBw9Y1PZ0a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Prelim Sales

Beat

$6 mln

$5.12 mln (3 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Hyperfine, Inc. is $2.00, about 135.6% above its October 7 closing price of $0.85


Reuters Recommended Reads

  • Oct 6 - Innovative Eyewear preliminary Q3 net sales rise to record high

  • Oct 8 - AngioDynamics Q1 sales beat on med tech segment growth

  • Oct 5 - Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Hyperfine

See all news